Dermatology biotech Krystal settles lawsuit from former partner as it prepares first FDA pitch

Krystal Biotech’s legal troubles with a small partner are over.

The Pittsburgh company settled its trade secrets dispute with PeriphaGen on Tuesday, agreeing to pay $25 million within 10 days of a final agreement and up to four additional payments of $12.5 million each depending on certain product milestones. Krystal admitted no wrongdoing as part of the settlement.